Prolonged therapy of hepatitis delta for 96 weeks with pegylated-interferon-α-2a plus tenofovir or placebo does not prevent hdv rna relapse after treatment: The hidit-2 study

Wedemeyer, H.Yurdaydin, C.Ernst, S.Caruntu, F. A.Curescu, M. G.Yalcin, K.Akarca, U. S.Gürel, SelimZeuzem, S.Erhardt, A.Lueth, S.Papatheodoridis, G. V.Keskin, O.Port, K.Radu, M.Celen, M. K.Ildeman, R.Stift, J.Heidrich, B.Mederacke, I.Hardtke, S.Koch, A.Dienes, H. P.Manns, M. P.HIDIT-2 Study Grp2024-08-152024-08-152014-04-010168-8278https://www.sciencedirect.com/science/article/pii/S0168827814600064https://hdl.handle.net/11452/44080Bu çalışma, 09-13, Nisan 2014 tarihlerinde London[İngiltere]’de düzenlenen 49. Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver Kongresi‘nde bildiri olarak sunulmuştur.eninfo:eu-repo/semantics/closedAccessScience & technologyLife sciences & biomedicineGastroenterology & hepatologyGastroenterology & hepatologyProlonged therapy of hepatitis delta for 96 weeks with pegylated-interferon-α-2a plus tenofovir or placebo does not prevent hdv rna relapse after treatment: The hidit-2 studyMeeting Abstract000361961700005S2S36011600-0641